Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
NCT ID: NCT04800237
Last Updated: 2024-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
230 participants
INTERVENTIONAL
2021-02-23
2022-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578
Novel Anxiety Treatment
NCT03790696
Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety
NCT05907967
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
NCT02922166
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
NCT06510504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VQW-765
VQW-765
oral capsule
Placebo
Placebo
oral capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VQW-765
oral capsule
Placebo
oral capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sufficiently fluent in English to participate in the trial.
* Male and female patients aged 18-70 years (inclusive).
Exclusion Criteria
* Current or planned pregnancy or nursing during the trial period.
* A positive test for substances of abuse.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Tempe, Arizona, United States
Vanda Investigational Site
Beverly Hills, California, United States
Vanda Investigational Site
Garden Grove, California, United States
Vanda Investigational Site
San Jose, California, United States
Vanda Investigational Site
Torrance, California, United States
Vanda Investigational Site
Orlando, Florida, United States
Vanda Investigational Site
Boston, Massachusetts, United States
Vanda Investigational Site
North Dartmouth, Massachusetts, United States
Vanda Investigational Site
Las Vegas, Nevada, United States
Vanda Investigational Site
Berlin, New Jersey, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
Staten Island, New York, United States
Vanda Investigational Site
Raleigh, North Carolina, United States
Vanda Investigational Site
Cincinnati, Ohio, United States
Vanda Investigational Site
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VQW-765-2201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.